EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma

Julianna Korns, Christina A Wicker, Maria Lehn, Shreya Shyamsunder, Samuel Thompson, Carissa Lester, Trisha M Wise-Draper, Susan E Waltz, Vinita Takiar

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217320 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Letters, 2024. Verfasst von Julianna Korns und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA; Department of Cancer Biology, University of Cincinnati, Cincinnati, …. Hauptthemen laut MEDLINE: Cisplatin, Radiation-Sensitizing Agents, Head and Neck Neoplasms, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NCI NIH HHS, NIDCR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of radiation treatment (RT) of head and neck squamous cell carcinoma (HNSCC) is limited by radioresistance and the toxicity of FDA approved radiosensitizers. In extension to our previous research where we demonstrated that telaglenastat (CB839) increased efficacy of RT in in vitro and in vivo HNSCC models, here, we examine the radiosensitizing effects of telaglenastat in comparison to cisplatin's, as cisplatin is currently the standard of care for concurrent therapy. Combination of telaglenastat with RT reduced tumor volume in a HNSCC patient derived xenograft mouse model. The efficacy of telaglenastat with RT in reducing cell survival and increasing apoptosis was similar if not greater than that of cisplatin with RT in Cal27 and HN5 HNSCC cells. The addition of telaglenastat increased reactive oxygen species and reduced the antioxidant glutathione in both Cal27 and HN5 cells. Reverse Phase Protein Array analyses revealed alterations in cell death and DNA damage response proteins. This study provides the scientific underpinnings for the use of telaglenastat as a radiosensitizer in the treatment of HNSCC either as an alternative to cisplatin or in cisplatin-ineligible patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinRadiation-Sensitizing AgentsHead and Neck NeoplasmsXenograft Model Antitumor AssaysSquamous Cell Carcinoma of Head and NeckApoptosisHumansAnimalsCell Line, TumorHydroxamic AcidsReactive Oxygen SpeciesMiceCarcinoma, Squamous CellCell SurvivalMice, NudeAntineoplastic AgentsDNA DamageChemoradiotherapy

Stichwörter der Autor:innen

CisplatinGlutaminase inhibitionHead and neck squamous cell carcinomaRadiosensitizerTelaglenastat

Substanzen

CisplatinRadiation-Sensitizing AgentsHydroxamic AcidsReactive Oxygen SpeciesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA; Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA.
  • Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA.
  • Cincinnati Medicine, University of Cincinnati, Cincinnati, OH, USA.
  • Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA.
  • Department of Internal Medicine, Division of Hematology Oncology, University of Cincinnati, Cincinnati, OH, USA.
  • Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA; Research Service, Cincinnati Veteran's Affairs Medical Center, Cincinnati, OH, USA.

Förderung

  • BLRD VA
  • NCI NIH HHS
  • NIDCR NIH HHS
  • NIEHS NIH HHS
  • U.S. Department of Veterans Affairs
  • National Institute of Dental and Craniofacial Research
  • US Department of Energy
  • National Cancer Institute

Zitieren

APA

Korns, J., Wicker, C. A., Lehn, M., Shyamsunder, S., Thompson, S., Lester, C., Wise-Draper, T. M., Waltz, S. E., & Takiar, V. (2024). Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217320

Vancouver

Korns J, Wicker CA, Lehn M, Shyamsunder S, Thompson S, Lester C, et al. Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217320

BibTeX
@article{Korns2024,
  author = {Korns, Julianna and Wicker, Christina A and Lehn, Maria and Shyamsunder, Shreya and Thompson, Samuel and Lester, Carissa and Wise-Draper, Trisha M and Waltz, Susan E and Takiar, Vinita},
  title = {Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217320}
}
Kostenlos starten →